Clinical Nephrology – Epidemiology – Clinical Trials
Kidney International (2004) 66, 2004–2009; doi:10.1111/j.1523-1755.2004.00971.x
Kidney and anemia in familial amyloidosis type I
IDALINA BEIRÃO, LUÍSA LOBATO, PAULO MP COSTA, ISABEL FONSECA, PAULA MENDES, MANUELA SILVA, FERNANDA BRAVO, ANTÓNIO CABRITA and GRAÇA PORTO
Departments of Nephrology, Endocrinology, Clinical Chemistry, and Hematology, Santo António General Hospital, Porto, Portugal; and Centro de Estudos de Paramiloidose, INSA Dr. Ricardo Jorge, Porto, Portugal
Correspondence: Idalina Beirão, M.D., Centro de Estudos de Paramiloidose, Hospital Geral de Santo António, Rua D. Manuel II, 4050–345, Porto, Portugal. E-mail:bbeirao@iol.pt
Received 1 October 2003; Revised 1 April 2004; Re-revised 2 May 2004; Accepted 20 May 2004.
Abstract
Kidney and anemia in familial amyloidosis type I.
Background
Familial amyloid polyneuropathy (FAP) type I is caused by a mutated transthyretin (TTR V30M) and characterized by a sensorimotor and autonomic neuropathy. Renal, cardiac, and ocular abnormalities can also occur. Anemia has been described in previous reports, but its prevalence in Portuguese FAP patients is not precisely known. The aim of this study was to estimate the prevalence of anemia in FAP type I Portuguese patients and to evaluate the contribution of erythropoietin (Epo) to its genesis.
Methods
A retrospective cross-sectional study was undertaken to determinate the prevalence and characteristics of anemia in 165 FAP patients. For comparison analysis, 3 control groups were also evaluated, 1 group of 46 apparently healthy subjects, 1 group of 17 asymptomatic carriers of FAP-trait, and a group of 14 non-FAP patients with chronic renal insufficiency. Serum Epo levels were analyzed in all groups.
Results
Anemia was present in 24.8% of symptomatic FAP patients. Iron stores, B12 vitamin, and serum folate levels were normal. FAP patients presented significantly lower serum Epo levels than healthy controls (P = 0.003). Epo levels were found lower than expected for the degree of anemia and in 17.5% were undetectable. Low Epo values were observed independently of the presence of renal failure or anemia, and sometimes preceded clinical disease.
Conclusion
Anemia in FAP type I is a common manifestation. The results clearly suggest a defective endogenous Epo production in the genesis of the anemia.
Keywords:
anemia, familial amyloid polyneuropathy, kidney, erythropoietin, amyloidosis, transthyretin
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
RESEARCH
Iron indices: What do they really mean?
Kidney International Article Response
Darbepoetin alfa (Aranesp?) in children with chronic renal failure
Kidney International Original Article
Kidney International Original Article
Kidney International Original Article


